First patients dosed in Phase 1b combination study in colorectal, gastric and ovarian cancer
Phase 1b trial will evaluate IVX037 and Innovent Bio’s anti-PD-1 inhibitor TYVYT® (sintilimab) in patients with late stage colorectal, gastric and ovarian cancer Trial open at 4 sites with further sites to open through Q4. Melbourne, Australia 28 October 2024 – ImmVirX Pty Limited, a clinical stage oncology company focused on developing next-generation, receptor targeted […]
